UniProt P78362 · PDB · AlphaFold · Substrate: RS peptide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Alectinib | 94.4% | 5.6% | 95.49 | 0.651 |
| 2 | Ceritinib | 69.4% | 30.6% | 95.44 | 0.618 |
| 3 | Repotrectinib | 45.3% | 54.8% | 84.21 | 0.608 |
| 4 | Defactinib | 45.2% | 54.8% | 92.68 | 0.450 |
| 5 | Capmatinib | 20.8% | 79.2% | 99.75 | 0.582 |
| 6 | Midostaurin | 19.5% | 80.5% | 78.64 | 0.500 |
| 7 | Pacritinib | 16.8% | 83.3% | 88.64 | 0.452 |
| 8 | Ruxolitinib | 14.7% | 85.3% | 98.25 | 0.592 |
| 9 | Vemurafenib | 12.9% | 87.1% | 96.49 | 0.598 |
| 10 | Brigatinib | 11.2% | 88.8% | 82.96 | 0.513 |
| 11 | Palbociclib | 10.4% | 89.6% | 98.75 | 0.673 |
| 12 | Bosutinib | 10.2% | 89.8% | 87.22 | 0.555 |
| 13 | Inavolisib | 9.3% | 90.7% | 100.00 | 0.679 |
| 14 | Baricitinib | 9.2% | 90.8% | 97.99 | 0.616 |
| 15 | Ponatinib | 9.2% | 90.8% | 78.23 | 0.534 |
| 16 | Entrectinib | 9.0% | 91.0% | 93.69 | 0.671 |
| 17 | Sunitinib | 8.9% | 91.1% | 91.73 | 0.524 |
| 18 | Crizotinib | 8.6% | 91.4% | 91.39 | 0.581 |
| 19 | Dasatinib | 8.3% | 91.7% | 87.97 | 0.699 |
| 20 | Afatinib | 8.1% | 91.9% | 98.50 | 0.709 |
Paralog block
SRPK1, SRPK2
EMT expression
- Mesenchymal log2(TPM+1): 4.78
- Epithelial log2(TPM+1): 4.44
- Fold change: 0.34
- Status: No significant change
High-confidence drugs
- Alectinib — inh 94.4% · KISS 36.42
- Ceritinib — inh 69.4% · KISS 12.27
- Repotrectinib — inh 45.3% · KISS -21.34
Selectivity landscape vs inhibition on SRPK2
Each point is one of the 92 approved drugs; color = inhibition % on SRPK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…